Eli Lilly (LLY): FY25 Q2 earnings call, Aug 7, 2025

Thu, Aug 7Earnings callSpeaker-labelled transcriptEli Lilly

No Kalshi or Polymarket word markets were listed for Eli Lilly’s Aug 7, 2025 earnings call (FY25 Q2). The transcript is searchable below (quotes of at most 25 words).

Updated

Transcript

quotes of at most 25 words

Speaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.

29 matches for “Zepbound”; 5 quoted, at least 25 words apart.

David A. Rickscompanyprepared

…our key products. These include Ebglyss, Jaypirca, Kisunla, Mounjaro, Omvoh, Verzenio and Zepbound. In the U.S., we continue the robust uptake of Zepbound and Mounjaro,…

David A. Rickscompanyprepared

…in CLL and SLL. And we launched the 2 highest doses of Zepbound in vials in the United States. We announced and closed the acquisition…

David A. Rickscompanyprepared

…affordable access to Lilly medicines. This includes our leading weight loss medications Zepbound at a discount of more than 50% off the list price. We…

Lucas E. Montarcecompanyprepared

…U.S. revenue increased 38% in Q2 driven by strong volume growth of Zepbound and Mounjaro, partially offset by an 8% decline in price. In Europe,…

Lucas E. Montarcecompanyprepared

…the recent CHMP positive opinion. Finally, moving to cardiometabolic drugs. Mounjaro and Zepbound both delivered impressive performance. Mounjaro posted $5.2 billion of global sales and…

Agents: this page as TSV at /api/v1/appearances/eli-lilly:2025-08-07:earnings_call · words: /api/v1/brief?appearance=eli-lilly:2025-08-07:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP